Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)
A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination With Carboplatin and Etoposide (PaCE) Chemotherapy Versus Carboplatin and Etoposide (CE) Alone in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer. The MATISSE Study
This is a multinational, multicenter, randomized controlled, open-label, adaptive study to evaluate the efficacy of palifosfamide-tris, carboplatin and etoposide (PaCE) chemotherapy in chemotherapy-naive subjects with extensive-stage small cell lung cancer (SCLC). Eligible subjects will be stratified according to age, gender, and Eastern Cooperative Oncology Group (ECOG) performance status, and randomized in a 1:1 ratio to receive either PaCE or carboplatin and etoposide (CE) chemotherapy.
The study design uses an adaptive group sequential approach with sample size re-estimation at the interim analysis.
Secondary efficacy endpoints include objective response rate (ORR), progression-free survival (PFS), duration of response and changes in quality of life (QOL) and disease-related symptoms. Tumor-related endpoints will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guidelines.
The safety of study treatments will be assessed by the frequency and severity of adverse events as determined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03. To provide an initial confirmation of safety, an early interim analysis of safety data only will be performed.
An independent Data Monitoring Committee (DMC) will be convened to assess the safety and efficacy of the study interventions and to monitor the overall conduct of the clinical trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New South Wales
-
Wollongong, New South Wales, Australia, 2500
- Southern Medical Day Oncology Care Centre
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
Ontario
-
Oshawa, Ontario, Canada, L1G 2B9
- R. S. McLaughlin Durham Regional Cancer Center at Lakeridge Health Oshawa
-
-
Quebec
-
Sainte-Foy, Quebec, Canada, G1V 4G5
- Hôpital Laval
-
-
-
-
-
Strasbourg, France, 67085
- Centre Paul Strauss
-
-
Auvergne-Rhône-Alpes
-
Pierre Bénité, Auvergne-Rhône-Alpes, France, 69495
- Centre Hospitalier Lyon Sud
-
-
Basse-normandie
-
Caen, Basse-normandie, France, 14076
- Centre François Baclesse
-
-
Brittany Region
-
Brest, Brittany Region, France, 29200
- Centre Hospitalier Universitaire -Hôpital Morvan
-
-
Centre-Val de Loire
-
Tours, Centre-Val de Loire, France, 97044
- Centre Hospitalier Universitaire, Hopital Bretonneau
-
-
Limousin, Lorraine
-
Limoges, Limousin, Lorraine, France, 87042
- Hôpital du Cluzeau
-
-
Pays de la Loire Region
-
Saint-Herblain, Pays de la Loire Region, France, 44805
- Institut de Cancérologie de l'Ouest - René Gauducheau
-
-
Provence-Alpes-Côte d'Azur Region
-
Marseille, Provence-Alpes-Côte d'Azur Region, France, 13008
- Hôpital Saint Joseph
-
-
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Hungary
- Debreceni Egyetem Orvos és Egészségtudományi Centrum
-
-
Heves County
-
Mátraháza, Heves County, Hungary
- Mátrai Gyógyintézet
-
-
-
-
-
Haifa, Israel
- Rambam Medical Center
-
Jerusalem, Israel, 91120
- Hadassah Medical Organization, Ein Kerem
-
Kfar Saba, Israel
- Meir Hospital Sapir Medical Center
-
Nahariya, Israel, 22100
- Western Gallilee Medical Center
-
Petah Tikva, Israel, 49100
- Rabin Medical Center Beilinson Campus
-
-
-
-
-
Genova, Italy
- Istituto Nazionale per la Ricerca sul Cancro
-
Milan, Italy, 20162
- Azienda Ospedaliera Ospedale Niguarda Ca' Granda
-
Trento, Italy, 38100
- Presidio Ospedaliero S. Chiara
-
-
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Poland
- Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie w Warszawie
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Poland
- Uniwersyteckie Centrum Kliniczne
-
Gdansk, Pomeranian Voivodeship, Poland
- Wojewódzkie Centrum Onkologii
-
-
West Pomeranian Voivodeship
-
Szczecin, West Pomeranian Voivodeship, Poland
- Specjalistyczny Szpital im. Alfreda Sokolowskiego
-
-
-
-
-
Chelaybinsk, Russia, 454087
- State Budget Institution of Healthcare "Chelyabinsk Regional Clinical Oncology Dispensary"
-
Ivanovo, Russia
- Ivanovo Regional Oncology Centre
-
Moscow, Russia
- Cancer Research Center n.a. N.N. Blokhin
-
Nizhny Novgorod, Russia, 603081
- GUZ of Nizhegorodskiy region, Nizhnij Novgorod City Oncology Dispensary
-
Saint Petersburg, Russia, 194044
- State Educational Institution "S.M. Kirov Military Medical Academy of Ministry of Defense of Russia"
-
Saint Petersburg, Russia
- Saint-Petersburg State Medical University n. a. I. P. Pavlov
-
Yaroslavl, Russia, 150040
- State healthcare institution of Yaroslavl region "Regional Clinical Oncologic Hospital"
-
-
Bashkortostan Republic
-
Ufa, Bashkortostan Republic, Russia, 450054
- Republic Clinical Oncology Dispensary of the Ministry of Healthcare of Republic of Bashkortostan
-
-
Moscow
-
Moscow Region, Moscow, Russia, 143423
- City Oncology Hospital # 62
-
-
Primorskiy (Maritime) Kray
-
Arkhangelsk, Primorskiy (Maritime) Kray, Russia, 163045
- State Institution of Healthcare "Arkhangelsk Regional Clinical Oncology Dispensary"
-
-
Tatarstan Republic
-
Kazan', Tatarstan Republic, Russia
- Republican Clinical Oncologic Dispensary of Ministry of health of Republic Tatarstan
-
-
-
-
-
Taichung, Taiwan, 40447
- China Medical University Hospital
-
-
-
-
England
-
Manchester, England, United Kingdom, M23 9LT
- Wythenshawe Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35205
- Birmingham Hematology and Oncology Associates, LLC
-
-
California
-
Los Angeles, California, United States, 90033
- University of Southern California
-
Santa Rosa, California, United States, 95403
- Redwood Regional Oncology Group
-
-
Delaware
-
Newark, Delaware, United States, 19713
- Christiana Care Health Services
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Baptist Cancer Institute
-
Port Saint Lucie, Florida, United States, 34952
- Hematology Oncology Associates of the Treasure Coast
-
-
Georgia
-
Atlanta, Georgia, United States, 30318
- Peachtree Hematology Oncology Consultants
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
Galesburg, Illinois, United States, 61401
- Medical and Surgical Specialists, LLC
-
Niles, Illinois, United States, 60714-5905
- Illinois Cancer Specialists
-
-
Indiana
-
Fishers, Indiana, United States, 46037
- Central Indiana Cancer Centers
-
Goshen, Indiana, United States, 46526
- Goshen Center for Cancer Care
-
Indianapolis, Indiana, United States, 46202
- Indiana University
-
Lafayette, Indiana, United States, 47905
- Horizon Oncology Center
-
Muncie, Indiana, United States, 47303
- Indiana University Health Ball Memorial Hospital
-
-
Kansas
-
Overland Park, Kansas, United States, 66210
- University of Kansas Hospital
-
-
Kentucky
-
Lexington, Kentucky, United States, 40503
- Central Baptist Hospital
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Medical Oncology, LLC
-
-
Maryland
-
Frederick, Maryland, United States, 21701
- Frederick Memorial Hospital Regional Cancer Therapy Center
-
-
Michigan
-
Wyoming, Michigan, United States, 49519
- Metro Health Cancer Center
-
-
Minnesota
-
Duluth, Minnesota, United States, 55805
- Saint Mary's Medical Center
-
Minneapolis, Minnesota, United States, 55407
- Virginia Piper Cancer Institute
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- John Theurer Cancer Center at Hackensack University Medical Center
-
Morristown, New Jersey, United States, 07962
- Hematology Oncology Associates of Northern New Jersey, PA, Carol G. Simon Cancer Center
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, United States, 12110-2188
- New York Oncology Hematology, PC
-
The Bronx, New York, United States, 10461
- Montefiore Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- The Christ Hospital
-
Dayton, Ohio, United States, 45429
- Dayton Cancer Center, Medical Oncology Hematology Associates
-
-
Pennsylvania
-
Kingston, Pennsylvania, United States, 18704
- Medical Oncology Associates Of Wyoming Valley, PC
-
-
South Carolina
-
Charleston, South Carolina, United States, 29403
- Charleston Hematology Oncology Associates, PA
-
-
Texas
-
Dallas, Texas, United States, 75230-6899
- Texas Oncology-Medical City Dallas
-
Dallas, Texas, United States, 75246
- Texas Oncology- Baylor, Charles A. Sammons Cancer Center
-
Galveston, Texas, United States, 77555-0565
- University of Texas Medical Branch at Galveston
-
Houston, Texas, United States, 77024
- Oncology Consultants, PA
-
Wichita Falls, Texas, United States, 76310-1610
- Texas Oncology, PA
-
-
Vermont
-
Burlington, Vermont, United States, 05405
- Fletcher Allen Health Care
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Fairfax Northern Virginia Hematology-Oncology, PC
-
-
Washington
-
Seattle, Washington, United States, 98104
- Swedish Medical Center
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53705
- Wisconsin Institutes for Medical Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Documented extensive-stage small cell lung cancer.
- Patient has received no prior chemotherapy, adjuvant therapy, or radiotherapy for lung cancer.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- Adequate bone marrow and organ function based on the results of protocol- specified laboratory tests.
- Male and female patients must agree to use a highly reliable method of birth control during study participation.
- Able to provide informed consent
Exclusion Criteria:
- Previously untreated (non-irradiated), symptomatic brain metastases.
- Known allergy to any of the study drugs or their excipients.
- Any unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a patient and/or their compliance with the protocol, based on screening tests, physical examination and medical history (as specifically defined in the clinical protocol).
- Any malignancy other than small cell lung cancer within the last 5 years prior to randomization, with the exception of cervical carcinoma in situ, nonmelanoma skin cancer, or superficial bladder tumors (Ta, Tis, or T1) that have been successfully and curatively treated with no evidence of recurrent or residual disease. (Exception: Subjects with a history of malignancy other than small cell lung cancer may be enrolled after consultation with the medical monitor provided the patient's prognosis is best defined by the extensive-stage small cell lung cancer).
- Currently pregnant or nursing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Palifosfamide-tris plus Carboplatin and Etoposide
Drug: palifosfamide-tris in combination with carboplatin and etoposide palifosfamide-tris: 130 mg/m2/day 3 days every 21 days for a max of 6 cycles. carboplatin: AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a max of 6 cycles. |
AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. 130 mg/m2/day 3 days every 21 days for a max of 6 cycles. 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles. AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles. |
|
Active Comparator: Carboplatin plus Etoposide
Drug: carboplatin in combination with etoposide carboplatin: AUC 5mg/mL/min 1 day every 21 days for a maximum of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles. |
AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles. AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall Survival (OS)
Time Frame: Assessed every 12 weeks for survival until 1 year following completion of enrollment
|
Assessed every 12 weeks for survival until 1 year following completion of enrollment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression Free Survival (PFS)
Time Frame: Assessed every 6 weeks for 22 weeks, then every 12 weeks until progressive disease, initiation of alternate anticancer therapy, or 1 year following the last patient enrolled (whichever is soonest)
|
Assessed every 6 weeks for 22 weeks, then every 12 weeks until progressive disease, initiation of alternate anticancer therapy, or 1 year following the last patient enrolled (whichever is soonest)
|
|
Objective Response Rate (ORR)
Time Frame: Assessed every 6 weeks for 22 weeks, then every 12 weeks until a partial or complete response is confirmed
|
Assessed every 6 weeks for 22 weeks, then every 12 weeks until a partial or complete response is confirmed
|
|
Response Duration
Time Frame: Time from the date of first objective response (partial or complete response), with subsequent confirmation, until the date of disease progression or the occurrence of death
|
Time from the date of first objective response (partial or complete response), with subsequent confirmation, until the date of disease progression or the occurrence of death
|
|
Quality of Life (QOL) as Assessed by the EuroQol 5-Dimension 3-Level Questionnaire (EQ-5D-3L) and the European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Module (QLQ-LC13)
Time Frame: Assessed every 3 weeks for 22 weeks, then every 12 weeks until 1 year following the last patient enrolled
|
Assessed every 3 weeks for 22 weeks, then every 12 weeks until 1 year following the last patient enrolled
|
|
Safety Parameters (Adverse Events and Number of Findings: Physical Examinations, Electrocardiograms [ECGs], Vital Signs, and Clinical Laboratory Results) Using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) 4.03
Time Frame: 22 weeks
|
22 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Small Cell Lung Carcinoma
- Organic Chemicals
- Hydrocarbons
- Hydrocarbons, Cyclic
- Carbohydrates
- Podophyllotoxin
- Tetrahydronaphthalenes
- Naphthalenes
- Polycyclic Aromatic Hydrocarbons
- Hydrocarbons, Aromatic
- Polycyclic Compounds
- Glucosides
- Glycosides
- Coordination Complexes
- Etoposide
- Carboplatin
- isophosphamide mustard
Other Study ID Numbers
Other Study ID Numbers
- IPM3002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.